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Purpose: Acute pulmonary embolism (PE) remains a significant cause of morbidity and 
requires prompt diagnosis and management. While non-surgical approaches have sup-
planted surgery as primary treatment, surgical pulmonary embolectomy (SPE) remains 
a vital option for select patients. We review the current management of acute PE, with a 
focus on surgical therapy.
Methods: A PubMed search was performed to identify literature regarding PE and 
treatment. Results were filtered to include the most comprehensive publications over the 
past decade.
Results: PE is stratified based on presenting hemodynamic status or degree of 
mechanical pulmonary arterial occlusion. Although systemic or catheter-guided 
fibrinolysis is the preferred first-line treatment for the majority of cases, patients 
who are not candidates should be considered for SPE. Studies demonstrate no mor-
tality benefit of thrombolysis over surgery. Systemic anticoagulation is a mainstay 
of treatment regardless of intervention approach. Following surgical embolectomy, 
direct oral anticoagulants (DOACs) have been shown to reduce recurrence of 
thromboembolism. 
Conclusions: Acute PE presents with varying degrees of clinical stability. Patients should 
be evaluated in the context of various available treatment options including medical, 
catheter-based, and surgical interventions. SPE is a safe and appropriate treatment 
option for appropriate patients.
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Acute pulmonary embolism (PE) is a significant cause 
of mortality worldwide, with over 100,000 deaths in 2018 
alone.1) It is the third most common cause of cardiovascu-
lar death among hospitalized patients in the Western 
world following acute myocardial infarction and stroke.2,3) 
Early diagnosis and intervention are paramount as most 
deaths from acute PE occur within the first several hours 
to days, with over 70% of deaths occurring within the 
first hour.4,5) The most common risk factor for PE is a 
history of prior deep vein thrombosis (DVT).2) However, 
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patients with underlying malignancy, those who have 
undergone a recent surgery, and those with history of 
hypercoagulability, such as factor V Leiden, also pose a 
greater risk of PE than the general population.6) These 
risk factors can be explained based on the pathogenesis of 
the DVT, commonly described using the Virchow’s Triad 
criteria: stasis of blood, hypercoagulability, and endothe-
lial vessel wall injury. Other risk factors that have been 
linked to acute PE include history of prolonged immobi-
lization, advanced age, obesity, smoking, stroke, conges-
tive heart failure, respiratory failure, sepsis, irritable 
bowel disease, pregnancy, hormone replacement therapy, 
and oral contraceptive use.2)
Although there are several classification systems, acute 
PE is defined as massive or submassive. The presence of 
any of the following criteria defines massive PE: hypoten-
sion or shock that results from right heart failure or cardio-
vascular collapse, a thrombus which occludes greater than 
50% of the pulmonary artery (PA) cross-sectional area or 
occludes two or more lobar arteries, or if the patient is 
dependent on inotropic agents.2,6–9) The pathophysiology 
of massive PE, summarized in Fig. 1, comprises a series of 
events that, if not treated rapidly, can lead to hemody-
namic instability, right heart failure, cardiogenic shock, 
cardiac arrest, and death within minutes to a few hours 
after the event.7,10–12) Massive PE accounts for approxi-
mately 4.5%–10% of all PE cases and carries substantial 
morbidity and mortality that exceeds 50%.1,2) Submassive 
PE is characterized by less severe clinical findings. These 
patients are often hemodynamically stable (systolic blood 
pressure >90 mmHg) but show signs of right heart strain, 
dysfunction, or injury on echocardiogram or by laboratory 
biomarkers.7) Common echocardiographic findings of 
submassive PE include right ventricular (RV) systolic dys-
function, RV dilation, or a RV/left ventricular (LV) 
diameter ratio of >0.9 on four chamber view. Laboratory 
studies found in submassive PE include BNP >90 pg/mL, 
N-terminal pro BNP >500 pg/mL, troponin I >0.4 ng/mL, 
or troponin T >0.1 ng/mL.9) RV injury can be demon-
strated on electrocardiogram (ECG) with new right bundle 
branch block or anteroseptal ST elevations, ST depres-
sions, or T-wave inversions.7)
Early recognition of acute PE allows for earlier diagnos-
tic and therapeutic management. While the presentation of 
acute PE can ranges from asymptomatic to sudden death, 
nearly 81% of patients will present with dyspnea, 70% 
with tachycardia, and 50% with hypoxia.6) Other common 
initial symptoms include pleuritic chest pain, syncope, 
hypotension, and hypocapnia.4) Contrast-enhanced com-
puted tomography (CT) and transesophageal echocardiog-
raphy (TEE) have 90%–95% sensitivity and 100% 
specificity for diagnosis of acute PE.13) TEE has the added 
benefit of being able to simultaneously assess both RV 
function and intracardiac thrombi. Ultrasound of the lower 
extremities should also be performed to identify DVT. CT 
pulmonary angiography is considered the gold standard of 
diagnosis for acute PE, although contrast-enhanced CT is 
the more commonly performed diagnostic test.8)
Fig. 1  Series of events after massive PE causing acute right ventricular heart failure. CO: cardiac output; LV: left 
ventricular; PAP: pulmonary artery pressure; PE: pulmonary embolism; PVR: pulmonary vascular resis-
tance; RV: right ventricular
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Therapeutic options for PE have been investigated for 
over a century, yet an established therapy algorithm has 
not been established due to rapid advances in surgical 
and non-surgical approaches. Currently available treat-
ment strategies for acute PE include systemic anticoagu-
lation, catheter-based fibrinolysis, systemic fibrinolysis, 
and surgical pulmonary embolectomy (SPE). This 
review provides an overview of the current management 
of acute PE, with a focus on surgical options.
Methods
We performed a search using the PubMed/MEDLINE 
database with the key terms “acute pulmonary embo-
lism,” “massive pulmonary embolism,” “submassive 
pulmonary embolism,” “surgical pulmonary embolec-
tomy,” and “fibrinolysis and pulmonary embolectomy.” 
We aimed to narrow our reference list to those which 
included multi-institutional studies when feasible. Sev-
eral single-institution studies were included if they 
included either a substantial number of patients or pre-
sented novel treatment options or algorithms.
Therapeutic Approaches
The treatment approach for acute PE should always 
consists of three major components: cardiopulmonary 
support, anticoagulation to prevent extension and recur-
rence, and reperfusion of the PA. Cardiopulmonary sup-
port should first be initiated with methods such as 
supplemental oxygen and inotropic agents. If the RV fails 
to respond appropriately with inotropes, then the initiation 
of more aggressive adjunctive measures such as surgery or 
extracorporeal membrane oxygenation (ECMO) should be 
strongly considered. Anticoagulation, usually with hepa-
rin, should be initiated as soon as PE is suspected unless 
the patient has a strong contraindication. Finally, reperfu-
sion of the PA should be achieved expeditiously (Fig. 2).4,9)
More than 70% of patients with massive PE receive 
advanced therapies for reperfusion of the PA, including 
systemic thrombolysis, catheter-directed thrombolysis 
(CDT), and SPE. Most patients can be successfully 
treated with non-surgical therapeutic interventions; the 
most frequently used is systemic thrombolysis, which 
has shown to decrease mortality rates to 2.4% in patients 
suffering from a massive PE.12) Systemic thrombolysis, 
however, carries concerns about bleeding, unnecessary 
systemic exposure of the thrombolytic agent, and length 
of time before treatment effectiveness (usually hours). 
Systemic thrombolysis generally requires tissue plas-
minogen activator (t-PA) infusion of 50–100 mg intrave-
nously (IV) over 1–2 hours and carries a 20% risk of 
major bleeding and a 2%–5% risk of hemorrhagic 
stroke.14) These limitations, along with technological 
Fig. 2  Acute PE reperfusion algorithm. PE: pulmonary embolism
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advances, led to the development of CDT which can 
target thrombolytic agent administration directly into the 
pulmonary arterial system. Indications for CDT in mas-
sive PE include contraindications to or failed systemic 
thrombolysis, or cardiogenic shock that is likely to cause 
death before systemic thrombolysis can take effect.
CDT is generally performed by infusing t-PA at a rate 
of 0.5–1 mg/h under ultrasound or fluoroscopic guid-
ance.14–17) Kuo et al. conducted a prospective multicenter 
study of CDT for acute PE in 101 patients. In this study, 
clinical success was defined as stabilization of hemody-
namics, improvement of pulmonary hypertension or 
right-sided heart strain, and survival to hospital discharge. 
In all, 28 of the 101 patients suffered from massive PE 
and immediate CDT achieved an 85.7% clinical success 
rate in this population with no major hemorrhagic com-
plications.17) Piazza and colleagues reported the results of 
the SEATTLE II study, a prospective, multicenter trial of 
CDT involving 150 patients throughout 22 states.14) 
All patients had massive or submassive PE less than 
14 days old with a RV to LV diameter ratio of at least 0.9. 
At 48 hours after CDT infusion, there was a 25% decrease 
in the RV/LV diameter, a 30% decrease in PA obstruction, 
and a 30% decrease in PA systolic pressure. No patients 
suffered fatal or intracranial hemorrhage, but there was a 
10% incidence of major bleeding events within 30 days 
after the procedure. These outcomes suggest that at expe-
rienced centers, CDT may be an appropriate and effective 
primary treatment strategy for acute PE.
Surgical Pulmonary Embolectomy
Historical perspective
Friedrich Trendelenburg was the first to report SPE in 
1908 at the 37th annual Congress of the German Surgi-
cal Association.18) He operated on three patients with 
acute PE and successfully extracted the thrombus, but no 
patient survived. His initial approach to SPE involved 
exposing the entire heart, making an incision in the 
conus arteriosus of the RV, and aspirating emboli from 
the PA with a veterinary syringe. His technique evolved 
to a small opening in the chest directly over the PA, 
occluding the aorta and main PA, and extracting emboli 
with forceps. In 1924, Martin Kirschner performed the 
first successful SPE on a 38-year-old woman who had 
collapsed on postoperative day 3 after an inguinal hernia 
repair.18) For historical context, heparin was first used 
for prophylaxis and treatment of venothromboembo-
lism (VTE) in 1936.4) Over the course of the century, as 
technique improved, so did patient outcomes. Arguably, 
the most important development was that of the cardio-
pulmonary bypass (CPB) machine. The first successful 
SPE utilizing CPB was in 1961, more than 100 years 
after Trendelenburg’s initial attempts.18)
Indications
The most recent guidelines from the American Heart 
Association and European Society of Cardiology outline 
indications for SPE (Table 1), including hemodynamic 
instability, failed thrombolysis, contraindications to 
thrombolysis, patent foramen ovale, thrombus-in-transit 
in the right-sided cardiac chambers, and patients who are 
predicted to die before realizing the benefits of thrombo-
lytics.9,19) Special considerations must be made for 
patients who are in the immediate postoperative period 
as these patients are at an increased risk of developing 
DVT and subsequent PE. In particular, recent intracra-
nial or spinal surgery within the past 2 months, any sur-
gical operation within the past 10 days, or recent 
intracranial hemorrhage are also indications for SPE ver-
sus thrombolytic therapy due to the high risk of hemor-
rhage. Pregnant and postpartum patients due to their 
high levels of estrogen are hypercoagulable and are 
therefore at an increased of DVT and acute PE. The use 
of thrombolysis in this population poses a risk of uterine 
hemorrhage, and therefore SPE may be indicated. Three 
case reports have been published on SPE during preg-
nancy which resulted in 100% maternal survival and 
25% fetal/neonatal mortality.4)
Approach
Patients with acute PE are at risk of sudden decom-
pensation during induction of general anesthesia due to 
loss of vascular tone and subsequent hypotension and 
loss of cardiac output. This risk can be addressed or 
Table 1 Indications for surgical pulmonary embolectomy
Massive or submassive PE with any of the following:
Contraindication to thrombolytic therapy
- History of intracranical hemorrhage
- Intracranial malignancy, mass, or aneurysm
- Cerebrovascular accident with the past 3 months
- Major surgery within the past 1 month




Right heart failure or cardiogenic shock
Thrombus-in-transit within the right sided heart chambers
PE: pulmonary embolism
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mitigated by either having bilateral groins prepped for 
rapid vascular access or initiating ECMO prior to induc-
tion.7) The incision of choice is midline sternotomy with 
central aortic and bicaval venous cannulation. CBP is 
initiated with an activated clotting time of >480 seconds 
and normothermia or mild systemic hypothermia. Car-
dioplegic arrest and aortic cross clamping are only indi-
cated if other cardiac procedures are to be performed, 
such as the retrieval of an intracardiac thrombus which 
can be visualized with intraoperative TEE.
Once on CPB, a longitudinal incision is made in the 
main PA with extension into the left proximal PA. The 
incision may be extended into the proximal right PA as 
necessary. Stay sutures on the edges of the arteriotomy 
assist with visualization exposure. The thrombus is usu-
ally immediately visible and can be extracted using for-
ceps, suction, or a Fogarty embolectomy catheter. To 
ensure optimal clot retrieval, a videoscope may be uti-
lized to visualize more distal arteries. In complex cases, 
additional procedures to remove peripheral clots may 
include retrograde perfusion whereby the left atrium is 
opened and oxygenated pump blood or saline is infused 
into the pulmonary veins which expels clots through the 
incision in the PA. The limitation of this maneuver is the 
requirement for cardioplegic arrest. Once all visible 
thrombus is removed, the pulmonary arteriotomy is 
closed and the patient weaned off CPB. If additional sup-
port is needed due to residual RV dysfunction, mechani-
cal circulatory support such as veno-arterial ECMO or a 
temporary right ventricular assist device (RVAD) can be 
initiated. Placement of an inferior vena cava (IVC) filter 
is considered standard of care following SPE due to the 
known increased risk of recurrent PE in these patients, 
although the timing of this procedure (whether intraoper-
ative at the time of SPE or postoperatively) is debated.20–22)
Outcomes
The International Cooperative Pulmonary Embolism 
Registry was the first multinational study to report the 
clinical outcomes of acute PE and identify factors associ-
ated with death.23) The study reported an overall 3-month 
mortality rate of 17.4% in a cohort of 2454 patients diag-
nosed with an acute PE. Kilic et al. examined the out-
comes of patients undergoing SPE and found an overall 
mortality of 27.2%, although this study did not stratify 
according to type of PE.24)
The Surgical Pulmonary Embolectomy as Routine 
therapy (SPEAR) working group reported an 11.7% 
in-hospital postoperative mortality, of which 23.7% had 
massive PE and 9.1% had submassive PE.25) Of interest, 
13.1% had CPR before SPE with a significant difference 
between the massive (34.2%) and the submassive (8.5%) 
PE groups. Massive PE was associated with significantly 
worse postoperative outcomes including blood product 
transfusion (76.3% vs. 36.4% for submassive) and pro-
longed mechanical ventilatory requirement (42.1% vs 
25%). 8.4% of patients required re-exploration for hem-
orrhage without a significant difference between the 
massive and the submassive PE groups. The SPEAR 
working group concluded that SPE is a safe procedure at 
high-volume centers that can be used more frequently to 
treat patients presenting with an acute massive PE or 
acute submassive PE.
Kon and associates reported the outcomes of SPE in 
North America and identified 1075 SPE cases among 310 
centers.26) The study population was not stratified based 
on massive and submassive PE, but on presentation status 
of no cardiogenic shock, cardiogenic shock without 
arrest, and cardiogenic shock with cardiac arrest. The car-
diac arrest group carried the highest mortality of 44.4%, 
followed by the shock without arrest group with 23.7%, 
and the no shock group with 7.9%. Kalra and colleagues 
performed a recent meta-analysis that demonstrated an 
in-hospital all-cause mortality of 26.3% for SPE. Among 
this population, 36.0% had preoperative contraindica-
tions to systemic thrombolysis, 33.9% suffered preopera-
tive cardiac arrest, and 27% required the use of ECMO.27) 
Not surprisingly, long-term mortality was greatest among 
those who suffered preoperative cardiac arrest and those 
who required preoperative ECMO. The investigators sug-
gested SPE as an appropriate management option in 
patients who show signs of RV dysfunction without 
hemodynamic instability as SPE can rapidly reduce RV 
strain and interrupt the progression to cardiogenic shock.
Other reports examining SPE outcomes from various 
time periods and of varying study sample size demon-
strate overall operative mortality ranging from 4.2% to 
30%.12,28–30) Numerous studies have shown improvements 
in SPE outcomes over time with significant 30%–70% 
decreases in mortality rate from the 1960s to the 
2000s.28,29) It is likely that the relatively higher mortality 
of SPE is attributable to the fact that patients undergoing 
SPE are, by definition, higher risk and higher acuity than 
those who undergo non-surgical management. Several 
investigators have shown no survival advantage of 
thrombolytic therapy over SPE.2,4,5,15,16) Significant hem-
orrhagic complications occur in nearly 25% of throm-
bolysis patients compared to 15% in SPE.5,15,31) Recurrent 
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PE is a known complication of all treatment modalities, 
but tend to occur more frequently following thromboly-
sis (21%) than SPE (7.7%).5,15,16) Regardless of treatment 
strategy, IVC filter placement should be performed either 
during the index procedure or shortly thereafter.
Postoperative management
Postoperative management following SPE can often be 
challenging due to the inherent critical nature of these 
patients. Bleeding, hypoxemia, RV dysfunction, and ongo-
ing cardiogenic shock must be treated aggressively balanc-
ing the need for volume infusion with aggressive right heart 
support. Inotropes and mechanical ventilatory support are 
routinely used, although there should be a low threshold to 
initiate mechanical circulatory support such as ECMO. RV 
dysfunction in these patients often resolves with time and 
adequate support, as long as the mechanical obstruction has 
been removed. Acute kidney injury is also common in these 
patients due to hypoperfusion due to impaired cardiac out-
put preoperatively or during CPB during surgery.8)
Postoperative anticoagulation is a necessary compo-
nent of postoperative management and serves to prevent 
recurrent PE.5) Studies indicate that with appropriate 
postoperative anticoagulation, the risk of recurrent PE is 
less than 5%.5) While low molecular weight heparin 
bridged to warfarin was once the treatment of choice, 
direct oral anticoagulants (DOACs) are now recom-
mended as the first-line therapy for most patients.7,32) 
DOACs including dabigatran, apixaban, rivaroxaban, 
and edoxaban have been shown to be non-inferior to 
warfarin in a series of large meta-analyses including the 
RE-COVER, RE-COVER II, EINSTEIN-DVT, EIN-
STEIN-PE, AMPLIFY, and Hokusai-VTE trials.33) In 
addition, DOACs have many potential advantages over 
warfarin, including rapid onset, decreased risk of bleed-
ing, fewer food and pharmaceutical interactions, and 
fewer monitoring requirements.32–34)
Prognosis 
While the morbidity and mortality associated with PE is 
greatest in the short term, these risks extend beyond the 
acute period in many patients. The overall 90-day mortality 
for acute PE is estimated at 15%.32) Prognosis varies greatly 
and may be predicted based on individual patient charac-
teristics. The Pulmonary Embolism Severity Index (PESI) 
and its simplified version (sPESI) are externally validated 
and simple tools which may be used to predict 30-day mor-
tality in patients suffering from acute PE.34) These tools 
rely on basic information which can be obtained on history 
and physical exam.34) PESI emphasizes history of underly-
ing malignancy and cardiopulmonary disease which are 
the most common long-term causes of death in acute PE 
patients.35) Patients who suffer from PE in the setting of 
underlying neoplasia have the worst prognosis.35)
Another reported predictor of prognosis is pulmonary 
artery pressure (PAP) at the time of diagnosis. Mean PAP 
≥30 mmHg is associated with a higher risk for pulmonary 
hypertension, ≥40 mmHg is associated with a 70% mortal-
ity rate, and >50 mmHg has a 90% mortality rate.32,35) 
Patients who survive an acute PE require close follow-up 
for the development of chronic thromboembolic pulmonary 
hypertension (CTEPH) and subsequent right heart failure.32)
Conclusion
Acute PE remains a highly morbid condition that 
requires prompt diagnosis and treatment. Several treatment 
modalities are available, ranging from systemic anticoagu-
lation in patients who have no signs of right heart dysfunc-
tion to systemic thrombolysis, catheter-directed therapy, 
and surgical embolectomy in patients with submassive and 
massive PE. Non-surgical approaches remain first-line 
therapy for most cases of PE, although select patient sub-
groups should be referred up front for surgical intervention 
as primary treatment. Surgical outcomes have improved 
substantially in the past decades and now offer a safe and 
appropriate treatment option that can reduce the mortality 
and morbidity associated with acute PE.
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